These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1788299)

  • 1. Metallothionein and oxidation reactions in Parkinson's disease.
    Ebadi M; Pfeiffer RF; Murrin LC; Shiraga H
    Proc West Pharmacol Soc; 1991; 34():285-90. PubMed ID: 1788299
    [No Abstract]   [Full Text] [Related]  

  • 2. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.
    Ebadi M; Sharma S; Muralikrishnan D; Shavali S; Eken J; Sangchot P; Chetsawang B; Brekke L
    Proc West Pharmacol Soc; 2002; 45():36-8. PubMed ID: 12434520
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Wallace DC; Shoffner JM; Watts RL; Juncos JL; Torroni A
    Ann Neurol; 1992 Jul; 32(1):113-4. PubMed ID: 1642467
    [No Abstract]   [Full Text] [Related]  

  • 4. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease.
    Ebadi M; Muralikrishnan D; Pellett LJ; Murphy T; Drees K
    Proc West Pharmacol Soc; 2000; 43():55-63. PubMed ID: 11056957
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biology of thioredoxin and its association with Alzheimer's disease and Parkinson's disease].
    Li LB; Liu GT
    Yao Xue Xue Bao; 2008 Jan; 43(1):1-8. PubMed ID: 18357724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 8. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins.
    Ebadi M; Sharma SK; Ghafourifar P; Brown-Borg H; El Refaey H
    Methods Enzymol; 2005; 396():276-98. PubMed ID: 16291239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation reactions in Parkinson's disease.
    Olanow CW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 32-7; discussion 37-9. PubMed ID: 2215972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nitroblue tetrazolium reduction by metallothionein.
    Shiraishi M; Utsumi K; Morimoto S; Joja I; Iida S; Takeda Y; Aono K
    Physiol Chem Phys; 1982; 14(6):533-7. PubMed ID: 6897906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum deposition in the central nervous system tissues of patients with Parkinson's disease].
    Yasui M; Kihira T; Ota K; Mukoyama M; Adachi K
    Rinsho Shinkeigaku; 1991 Oct; 31(10):1095-8. PubMed ID: 1802464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bioavailability in the treatment of Parkinson's disease.
    Seeberger LC; Hauser RA
    Neuropharmacology; 2007 Dec; 53(7):791-800. PubMed ID: 17936857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox imbalance.
    Berg D; Youdim MB; Riederer P
    Cell Tissue Res; 2004 Oct; 318(1):201-13. PubMed ID: 15365815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of Parkinson's disease: a possibility of oxidation].
    Jiménez-Jiménez FJ; Molina JA; Fernández-Calle P; Cabrera-Valdivia F
    Neurologia; 1993 Apr; 8(4):138-46. PubMed ID: 8517962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.